On October 13, 2026, the Scottish Medicines Consortium (SMC) accepted AbbVie’s AQUIPTA (atogepant) for the acute treatment of migraine in eligible adults within NHS Scotland. The decision adds a treatment option for patients and follows earlier recommendations and authorizations in the UK.
Separately, AbbVie shares reached a new 52-week high. The rise was reportedly driven by strong growth expectations for Skyrizi and Rinvoq, which are helping offset declining Humira sales.
Analysts maintained a positive outlook, with some reaffirming Buy ratings. They cited the performance of Skyrizi and Rinvoq and positive long-term clinical data presented at a recent conference.